Skip to main content
UC San Diego Innovation Innovation
  1. HOME
  2. About OIC
  3. Programs
  4. IPGaia

Medical researchers in a labIPGaia

In an effort to enhance the university's impact on improving lives and advancing research and entrepreneurship, UC San Diego has launched a new program in collaboration with IPG, called IPGaia. The goal of IPGaia is to accelerate the development of innovative drug candidates. This initiative allows UC San Diego to propose drug targets to IPG for the identification and development of lead compounds, with the goal of licensing them to pharmaceutical companies. This partnership is an open invitation to academia and industry players to submit promising drug leads, aiming to fast-track the creation of highly personalized treatments. 

 Read more about this partnership: IPGaia, Inc. and UC San Diego Announce Master Collaborative Research and Development Agreement

 

About IPG

Established in 2021, IPGaia (IPG) promotes research and development with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies. By collaborating among the parties to build a next stage drug discovery platform, it would be possible to generate high quality innovative pharmaceuticals in a shorter period of time and lower cost. As for the pharmaceutical industry, the trend of the horizontal division of labor business model would be more accelerating. IPG plays a role as a platformer for creating pre-clinical stage innovative new medicines.


  

Review Proposal Template

Program Goal

To create licensable pre-clinical stage assets mainly for pharmaceutical companies and VCs with new IP, data and clinical candidate compounds.

Project Scope

The scope is limited to therapeutics and vaccines and does not include diagnostics and devices. There is no limitation in therapeutic areas and modalities (mRNA is preferred). Any research stage from drug discovery concept/target to pre-clinical stage candidate compound will be accepted. There is no requirement of background IP.

Program Selection Criteria

Selection will be focused on human disease relevance and unmet medical needs with ideas or approaches for validation of your concept to fill the gap. Please detail your competitive advantage over the current treatment and value proposition.